Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma-Reference-Cited by-同舟云学术

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma

Published:2018-07-19 Issue:1 Volume:33 Page:266-270
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Aldoss Ibrahim,Capelletti Marzia,Park Jihye,Pistofidis Romanos Sklavenitis,Pillai Raju,Stiller Tracey,Sanchez James F.,Forman Stephen J.,Ghobrial Irene M.,Krishnan Amrita

Funder

Foundation for the National Institutes of Health (Foundation for the National Institutes of Health, Inc.)

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0213-y.pdf

Reference18 articles.

1. Razavi P, Rand KA, Cozen W, Chanan-Khan A, Usmani S, Ailawadhi S. Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. Blood Cancer J. 2013;3:e121.

2. Jonsdottir G, Lund SH, Bjorkholm M, Turesson I, Hultcrantz M, Porwit A, et al. The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. Blood Adv. 2017;1:2392–8.

3. Barlogie B, Tricot G, Haessler J, van Rhee F, Cottler-Fox M, Anaissie E, et al. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989. Blood. 2008;111:94–100.

4. Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, et al. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance. Blood. 2012;120:1597–1600.

5. Rollison DE, Komrokji R, Lee JH, Hampras S, Fulp W, Fisher K, et al. Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide. Leuk Lymphoma. 2017;58:560–8.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Role of epigenetic in cancer biology, in hematologic malignancies and in anticancer therapy;Frontiers in Molecular Medicine;2024-09-06

2. Characteristics and outcomes of secondary acute lymphoblastic leukemia (sALL) after multiple myeloma (MM): SEER data analysis in a single-center institution;Cancer Pathogenesis and Therapy;2024-07

3. The risk and survival of multiple myeloma as the second primary malignancy in a single Chinese center;Translational Cancer Research;2024-06

4. Allogeneic hematopoietic cell transplantation is equally effective in secondary acute lymphoblastic leukemia (ALL) compared to de-novo ALL—a report from the EBMT registry;Bone Marrow Transplantation;2024-01-09

5. B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature;Leukemia & Lymphoma;2023-07-17